New EU contraindication and warnings for Novartis's aliskiren
This article was originally published in Scrip
Executive Summary
The CHMP wants changes to the labels of products containing Novartis's troubled anithypertensive aliskiren that will massively curtail its recommended patient population, but it has stopped short of recommending the drug's removal from the market.